Tirazone (Cervical Cancer) – Analysis and Forecasts to 2020

Date: October 1, 2011
Pages: 22
Price:
US$ 2,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T77F8509347EN
Leaflet:

Download PDF Leaflet

Tirazone (Cervical Cancer) – Analysis and Forecasts to 2020
Tirazone (Cervical Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “ Tirazone ( Cervical Cancer) - Analysis and Forecasts to 2020” provides Tirazone sales forecasts for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Cervical Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Summary
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Tirazone including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Tirazone including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2012-2020 for Tirazone in the US

Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Cervical Cancer Market
2.2 Epidemiology
2.3 Etiology
  2.3.1 HPV Infections
  2.3.2 Lack of Regular Papanicolaou (pap) Tests
  2.3.3 Smoking
  2.3.4 Sexual History
  2.3.5 Birth Control Pills
2.4 GlobalData Pipeline Report Guidance

3 CERVICAL CANCER DISEASE: MARKET CHARACTERIZATION

3.1 Cervical Cancer Disease Market
3.2 Cervical Cancer Disease Market Forecasts and CAGR
3.3 Drivers and Barriers for the Cervical Cancer Market

4 TUMOR-NODE-METASTASES (TNM) CLASSIFICATION OF CERVICAL CANCER

5 TIRAZONE (TIRAPAZAMINE)

5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Factors Affecting Sales of Tirazone
  5.4.1 High Efficacy
  5.4.2 Competition
  5.4.3 Marketing Rights
5.5 Drug Risk Benefit Score
  5.5.1 Efficacy
  5.5.2 Safety
  5.5.3 Compliance
  5.5.4 Dosing Convenience
5.6 Intensity of Competition
5.7 Sales forecast
  5.7.1 Target patient Pool of Tirazone
  5.7.2 Dosing
  5.7.3 Market Penetration
  5.7.4 Annual Cost of Therapy
  5.7.5 Sales Projections of Tirazone

6 CERVICAL CANCER MARKET: APPENDIX

6.1 Market Definitions
6.2 Abbreviations
6.3 Research Methodology
  6.3.1 Coverage
  6.3.2 Secondary Research
  6.3.3 Forecasting
  6.3.4 Number of Patients Approved to take the Drug
  6.3.5 Net Penetration of Drug
  6.3.6 Net Annual Dosing
  6.3.7 Annual Cost of Therapy
  6.3.8 Primary Research
  6.3.9 Expert Panels
6.4 Contact Us
6.5 Disclaimer
6.6 Sources

LIST OF TABLES

Table 1: Cervical Cancer, Incidences and Mortality, 2008–2030
Table 2: Cervical Cancer, US,EU-5 and Japan, Market Size Forecast ($m), 2009–2020
Table 3: Drug Risk Benefit Score of Tirazone
Table 4: Tirazone, Cervical Cancer, The US, Sales Forecast ($m), 2012–2020

LIST OF FIGURES

Figure 1: Distribution of Incidence and Mortality of Top 26 Diagnosed Cancers, Global, 2010
Figure 2: Difference Between Percentage Distribution of Incidence and Mortality of Top 19 Cancers, 2008
Figure 3: Cervical Cancer, US,EU-5 and Japan, Market Size Forecast ($m), 2009–2020
Figure 4: Classification of Cervical Cancer
Figure 5: TNM Staging Classification
Figure 6: Classification of Cervical Cancer
Figure 7: Drug Model Diagram of Tirazone
Figure 8: Tirazone, Cervical Cancer, The US, Sales Forecast ($m), 2012–2020
Figure 9: GlobalData Methodology
Figure 10: Drug Model Diagram
Figure 11: Patients Approved for the Drug

Ask Your Question

Tirazone (Cervical Cancer) – Analysis and Forecasts to 2020
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: